SEC Form 4
Adaptive Biotechnologies Corporation (ADPT) insider trading
In the 12 months to Oct 26, 2026, 11 ADPT insiders reported open-market sales of $111.3M across 68 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $111.3M
- 68 filings · 11 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 62 of 68
- $91.7M of $111.3M sold (82%)
Who traded ADPT, and when
- Sale
- Sale, pre-arranged (10b5-1)
ADPT daily close from Oct 27, 2025 to Oct 26, 2026, between $12.41 and $29.84, last $26.28. 68 sale and 0 purchase filings by 11 insiders, marked at their filing dates. Chad M. Robins, CEO and Chairman: sold $33.6M across 7 filings, first filed Nov 12, 2025, last Aug 19, 2026. Harlan S. Robins, Chief Scientific Officer: sold $23.5M across 9 filings, first filed Nov 12, 2025, last Jul 23, 2026. Julie Rubinstein, President and COO: sold $16.4M across 19 filings, first filed Mar 5, 2026, last Oct 21, 2026. Sharon Benzeno, Chief Commercial Ofc Imm Med: sold $13.9M across 3 filings, first filed Nov 24, 2025, last Jun 30, 2026. Francis Lo, Chief People Officer: sold $13.3M across 11 filings, first filed Dec 17, 2025, last Oct 5, 2026. Kyle Piskel, Chief Financial Officer: sold $3.3M across 3 filings, first filed Dec 2, 2025, last Feb 6, 2026. 5 others: sold $7.4M across 16 filings, first filed Dec 12, 2025, last Oct 8, 2026.
Largest mark · tap a row for others
Chad M. Robins · CEO and Chairman
Sale $14,882,166
600,000 shares at $24.80 avg
Filed Aug 19, 2026 · traded Aug 17
Close on filing date $25.49
Chad M. Robins · CEO and Chairman
CEO and Chairman
$33.6M soldHarlan S. Robins · Chief Scientific Officer
Chief Scientific Officer
$23.5M soldJulie Rubinstein · President and COO
President and COO
$16.4M soldSharon Benzeno · Chief Commercial Ofc Imm Med
Chief Commercial Ofc Imm Med
$13.9M soldFrancis Lo · Chief People Officer
Chief People Officer
$13.3M soldKyle Piskel · Chief Financial Officer
Chief Financial Officer
$3.3M sold5 others
Combined, one mark per week
$7.4M soldOpen-market trades
68 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Chad M. Robins | CEO and Chairman | $33.6M | — | 7 | 56% of sales | |
| Harlan S. Robins | Chief Scientific Officer | $23.5M | — | 9 | 100% of sales | |
| Julie Rubinstein | President and COO | $16.4M | — | 19 | 100% of sales | |
| Sharon Benzeno | Chief Commercial Ofc Imm Med | $13.9M | — | 3 | 100% of sales | |
| Francis Lo | Chief People Officer | $13.3M | — | 11 | 100% of sales | |
| Kyle Piskel | Chief Financial Officer | $3.3M | — | 3 | 100% of sales | |
| Peter M. Neupert | Director | $3.1M | — | 1 | — | |
| Michelle Renee Griffin | Director | $2.0M | — | 3 | 89% of sales | |
| Robert Hershberg | Director | $1.1M | — | 2 | — | |
| Susan Bobulsky | Chief Commercial Officer, MRD | $853.0K | — | 9 | 100% of sales | |
| Katey Einterz Owen | Director | $250.0K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 35,643 | $24.66 | $879.1K | 377,802 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 35,643 | $25.18 | $897.4K | 378,102 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 35,643 | $25.81 | $919.9K | 377,802 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 35,643 | $26.60 | $948.2K | 377,802 | |
traded | Susan Bobulsky Chief Commercial Officer, MRD | SalePre-arranged (10b5-1) | 6,444 | $30.00 | $193.3K | 389,350 | |
traded | Francis Lo Chief People Officer | SalePre-arranged (10b5-1) | 26,792 | $28.28 | $757.7K | 220,867 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 35,643 | $28.46 | $1.0M | 377,802 | |
traded | Francis Lo Chief People Officer | SalePre-arranged (10b5-1) | 115,406 | $28.06 | $3.2M | 220,867 | |
traded | Susan Bobulsky Chief Commercial Officer, MRD | SalePre-arranged (10b5-1) | 1,195 | $27.00 | $32.3K | 395,794 | |
traded | Katey Einterz Owen Director | Sale | 9,615 | $26.00 | $250.0K | 78,639 | |
traded | Robert Hershberg Director | Sale | 30,664 | $24.40 | $748.2K | 46,683 | |
traded | Peter M. Neupert Director | Sale | 124,690 | $25.15 | $3.1M | 240,315 | |
traded | Chad M. Robins CEO and Chairman | Sale | 600,000 | $24.80 | $14.9M | 2,180,722 | |
traded | Susan Bobulsky Chief Commercial Officer, MRD | SalePre-arranged (10b5-1) | 3,000 | $25.00 | $75.0K | 396,989 | |
traded | Susan Bobulsky Chief Commercial Officer, MRD | SalePre-arranged (10b5-1) | 1,299 | $24.00 | $31.2K | 399,989 | |
traded | Harlan S. Robins Chief Scientific Officer | SalePre-arranged (10b5-1) | 492,400 | $21.89 | $10.8M | 812,058 | |
traded | Susan Bobulsky Chief Commercial Officer, MRD | SalePre-arranged (10b5-1) | 5,000 | $23.00 | $115.0K | 401,288 | |
traded | Francis Lo Chief People Officer | SalePre-arranged (10b5-1) | 105,762 | $22.59 | $2.4M | 230,713 | |
traded | Harlan S. Robins Chief Scientific Officer | SalePre-arranged (10b5-1) | 386,240 | $22.01 | $8.5M | 1,166,547 | |
traded | Francis Lo Chief People Officer | SalePre-arranged (10b5-1) | 95,842 | $22.51 | $2.2M | 230,713 | |
traded | Susan Bobulsky Chief Commercial Officer, MRD | SalePre-arranged (10b5-1) | 487 | $22.00 | $10.7K | 406,288 | |
traded | Sharon Benzeno Chief Commercial Ofc Imm Med | SalePre-arranged (10b5-1) | 165,802 | $21.13 | $3.5M | 221,278 | |
traded | Michelle Renee Griffin Director | SalePre-arranged (10b5-1) | 52,084 | $20.18 | $1.1M | 15,625 | |
traded | Susan Bobulsky Chief Commercial Officer, MRD | SalePre-arranged (10b5-1) | 5,000 | $20.50 | $102.5K | 406,775 | |
traded | Harlan S. Robins Chief Scientific Officer | SalePre-arranged (10b5-1) | 106,160 | $17.41 | $1.8M | 1,405,898 | |
traded | Susan Bobulsky Chief Commercial Officer, MRD | SalePre-arranged (10b5-1) | 5,000 | $19.00 | $95.0K | 411,775 | |
traded | Francis Lo Chief People Officer | SalePre-arranged (10b5-1) | 39,741 | $17.49 | $695.1K | 250,934 | |
traded | Susan Bobulsky Chief Commercial Officer, MRD | SalePre-arranged (10b5-1) | 11,000 | $18.00 | $198.0K | 416,775 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 19,037 | $14.23 | $270.9K | 377,802 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 57,180 | $13.96 | $798.4K | 382,132 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 69,061 | $14.60 | $1.0M | 395,146 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 57,180 | $14.45 | $826.3K | 408,160 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 57,180 | $13.26 | $758.1K | 424,512 | |
traded | Francis Lo Chief People Officer | SalePre-arranged (10b5-1) | 22,564 | $15.07 | $340.0K | 271,154 | |
traded | Harlan S. Robins Chief Scientific Officer | SalePre-arranged (10b5-1) | 10,000 | $14.85 | $148.5K | 1,512,058 | |
traded | Chad M. Robins CEO and Chairman | SalePre-arranged (10b5-1) | 120,595 | $14.65 | $1.8M | 2,180,518 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 69,061 | $14.34 | $990.5K | 434,288 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 38,120 | $14.53 | $553.7K | 447,202 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 57,180 | $13.14 | $751.3K | 455,878 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 57,180 | $14.03 | $802.2K | 468,892 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 57,180 | $13.46 | $769.6K | 481,906 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 57,180 | $13.33 | $762.2K | 494,920 | |
traded | Michelle Renee Griffin Director | Sale | 15,394 | $13.91 | $214.1K | 15,625 | |
traded | Francis Lo Chief People Officer | SalePre-arranged (10b5-1) | 30,593 | $14.08 | $430.7K | 291,374 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 57,180 | $13.30 | $760.4K | 507,934 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 81,342 | $14.90 | $1.2M | 643,471 | |
traded | Michelle Renee Griffin Director | SalePre-arranged (10b5-1) | 48,044 | $15.30 | $735.1K | 15,394 | |
traded | Julie Rubinstein President and COO | SalePre-arranged (10b5-1) | 92,823 | $16.09 | $1.5M | 575,235 | |
traded | Harlan S. Robins Chief Scientific Officer | SalePre-arranged (10b5-1) | 24,233 | $16.19 | $392.3K | 1,155,291 | |
traded | Chad M. Robins CEO and Chairman | SalePre-arranged (10b5-1) | 524,998 | $15.85 | $8.3M | 1,934,247 | |
traded | Kyle Piskel Chief Financial Officer | SalePre-arranged (10b5-1) | 2,145 | $18.46 | $39.6K | 216,637 | |
traded | Chad M. Robins CEO and Chairman | SalePre-arranged (10b5-1) | 124,998 | $18.44 | $2.3M | 2,459,245 | |
traded | Harlan S. Robins Chief Scientific Officer | SalePre-arranged (10b5-1) | 42,788 | $18.68 | $799.1K | 1,179,524 | |
traded | Francis Lo Chief People Officer | SalePre-arranged (10b5-1) | 79,590 | $17.73 | $1.4M | 315,978 | |
traded | Kyle Piskel Chief Financial Officer | SalePre-arranged (10b5-1) | 4,290 | $18.00 | $77.2K | 216,637 | |
traded | Harlan S. Robins Chief Scientific Officer | SalePre-arranged (10b5-1) | 10,000 | $16.44 | $164.4K | 1,222,312 | |
traded | Chad M. Robins CEO and Chairman | SalePre-arranged (10b5-1) | 124,998 | $15.59 | $1.9M | 2,584,243 | |
traded | Francis Lo Chief People Officer | SalePre-arranged (10b5-1) | 4,394 | $17.50 | $76.9K | 315,978 | |
traded | Francis Lo Chief People Officer | SalePre-arranged (10b5-1) | 3,125 | $16.08 | $50.2K | 315,978 | |
traded | Francis Lo Chief People Officer | SalePre-arranged (10b5-1) | 113,890 | $15.57 | $1.8M | 315,978 | |
traded | Robert Hershberg Director | Sale | 22,968 | $16.00 | $367.5K | 46,722 | |
traded | Sharon Benzeno Chief Commercial Ofc Imm Med | SalePre-arranged (10b5-1) | 12,604 | $16.85 | $212.4K | 296,791 | |
traded | Harlan S. Robins Chief Scientific Officer | SalePre-arranged (10b5-1) | 37,212 | $18.07 | $672.5K | 1,232,312 | |
traded | Kyle Piskel Chief Financial Officer | SalePre-arranged (10b5-1) | 162,820 | $19.50 | $3.2M | 216,637 | |
traded | Chad M. Robins CEO and Chairman | SalePre-arranged (10b5-1) | 160,734 | $19.10 | $3.1M | 2,709,241 | |
traded | Sharon Benzeno Chief Commercial Ofc Imm Med | SalePre-arranged (10b5-1) | 606,402 | $16.73 | $10.1M | 296,791 | |
traded | Chad M. Robins CEO and Chairman | SalePre-arranged (10b5-1) | 89,265 | $14.73 | $1.3M | 2,869,975 | |
traded | Harlan S. Robins Chief Scientific Officer | SalePre-arranged (10b5-1) | 10,000 | $14.82 | $148.2K | 1,269,524 |
GET /stocks/filings/vX/form-4?tickers=ADPT&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ADPT"
],
"issuer_cik": "0001478320",
"owner_cik": "0001780664",
"accession_number": "0001780664-26-000043",
"form_type": "4",
"filing_date": "2026-10-21",
"period_of_report": "2026-10-19",
"issuer_name": "Adaptive Biotechnologies Corp",
"issuer_trading_symbol": "ADPT",
"owner_name": "RUBINSTEIN JULIE",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President and COO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-19",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 11881,
"transaction_price_per_share": 24.05,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 377802,
"transaction_value": 285738.05,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025."
},
{
"id": "F2",
"description": "The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.88 to $24.85, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4."
}
]
},
{
"tickers": [
"ADPT"
],
"issuer_cik": "0001478320",
"owner_cik": "0001780664",
"accession_number": "0001780664-26-000043",
"form_type": "4",
"filing_date": "2026-10-21",
"period_of_report": "2026-10-19",
"issuer_name": "Adaptive Biotechnologies Corp",
"issuer_trading_symbol": "ADPT",
"owner_name": "RUBINSTEIN JULIE",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President and COO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-21",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 5999,
"transaction_price_per_share": 25.25,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 383684,
"transaction_value": 151474.75,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025."
},
{
"id": "F4",
"description": "The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.44 to $25.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 152 records
- Option exercises126 records
- Tax withholding (sold to cover)11 records
- Grants and awards14 records
- Gifts1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has the Adaptive Biotechnologies Corporation's CEO sold stock?
Yes. Chad M. Robins (CEO) sold 1,745,588 shares ($33.6M) between Nov 2025 and Aug 2026, $18.7M of it under a pre-arranged 10b5-1 plan.
How current is ADPT’s insider data?
These are ADPT Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ADPT insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ADPT every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.